ANNOVIS BIO (ANVS:NYSE)
$1.59 -0.03 (-1.8519%)
Analysed ANNOVIS BIO (ANVS:NYSE) News Sources
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
10-04-2026
yahoo.com
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
09-04-2026
yahoo.com
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
02-04-2026
yahoo.com
Annovis Publishes Historical Review of Buntanetap in The Scientist
31-03-2026
yahoo.com
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
19-03-2026
yahoo.com
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
19-03-2026
yahoo.com
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
16-03-2026
yahoo.com
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
03-03-2026
yahoo.com
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
12-02-2026
yahoo.com
Automotive Night Vision System Market to Reach US$ 9,138.4 Million by 2032 Driven by AI-Enabled Predictive Safety and Mainstream Adoption Beyond Luxury Vehicles | Astute Analytica
10-02-2026
yahoo.com
What is the current price of ANNOVIS BIO (ANVS:NYSE)?
The current price of ANNOVIS BIO (ANVS:NYSE) is $1.59.
ANNOVIS BIO (ANVS:NYSE) absolute price change since previous trading day?
The absolute price change of ANNOVIS BIO (ANVS:NYSE) since the previous trading day is $-0.03.
ANNOVIS BIO (ANVS:NYSE) percentage price change since previous trading day?
The percentage price change of ANNOVIS BIO (ANVS:NYSE) since the previous trading day is -1.8519%.
What is the most recent average sentiment score for ANNOVIS BIO (ANVS:NYSE)?
The most recent average sentiment score for ANNOVIS BIO (ANVS:NYSE) is 88 out of 100.
What is the most recent average sentiment for ANNOVIS BIO (ANVS:NYSE)?
The most recent sentiment for ANNOVIS BIO (ANVS:NYSE) is .
SEC-8K** Filing Available For ANNOVIS BIO (ANVS:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.